newsfilter
← Latest News
PR Newswire·

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

The Company is working closely with its commercial partners to supply the combination therapy to patients in need Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China N